SCHOTT PHARMA AG & CO. KGAA SCHOTT Pharma AG & Co. KGaA Stock
Equities
1SXP
DE000A3ENQ51
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.3 EUR | +2.81% |
|
-3.87% | -12.80% |
| May. 28 | SCHOTT PHARMA : Berenberg reiterates its Neutral rating | ZD |
| May. 21 | Deutsche Bank Research lowers target for Schott Pharma - 'Buy' | DP |
| Sales 2024 * | 976M 1.06B | Sales 2025 * | 1.1B 1.19B | Capitalization | 4.41B 4.79B |
|---|---|---|---|---|---|
| Net income 2024 * | 144M 156M | Net income 2025 * | 167M 181M | EV / Sales 2024 * | 4.72 x |
| Net Debt 2024 * | 200M 217M | Net Debt 2025 * | 188M 204M | EV / Sales 2025 * | 4.18 x |
| P/E ratio 2024 * |
30.4
x | P/E ratio 2025 * |
26.6
x | Employees | 4,687 |
| Yield 2024 * |
0.53% | Yield 2025 * |
0.62% | Free-Float | 19.7% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.81% | ||
| 1 week | -3.87% | ||
| 1 month | -25.48% | ||
| 3 months | -25.63% | ||
| 6 months | +1.74% | ||
| Current year | -12.80% |
1 week
27.90
30.94
1 month
27.9038.92
Current year
27.9043.40
1 year
27.0043.40
3 years
27.0043.40
5 years
27.0043.40
10 years
27.0043.40
| Managers | Title | Age | Since |
|---|---|---|---|
Andreas Reisse
CEO | Chief Executive Officer | 63 | 22-06-30 |
| Director of Finance/CFO | 43 | 22-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eva Kienle
BRD | Director/Board Member | 57 | 23-04-03 |
Wolfgang Wienand
BRD | Director/Board Member | 52 | 23-04-03 |
| Chairman | 59 | 23-04-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 29.3 | +2.81% | 166,058 |
| 24-05-30 | 28.5 | -0.14% | 76,594 |
| 24-05-29 | 28.54 | -5.56% | 64,659 |
| 24-05-28 | 30.22 | -1.31% | 42,486 |
| 24-05-27 | 30.62 | +0.46% | 18,265 |
Delayed Quote Xetra, May 31, 2024 at 11:39 am EDT
More quotes
SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The Company's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.
Calendar
2024-06-26
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
29.3
EUR
Average target price
34.84
EUR
Spread / Average Target
+18.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.80% | 4.79B | |
| -7.16% | 178B | |
| -1.23% | 107B | |
| -4.86% | 67.04B | |
| -4.28% | 47.23B | |
| +10.32% | 44.62B | |
| +8.14% | 42.5B | |
| +15.76% | 29.99B | |
| +15.53% | 25.22B | |
| -5.88% | 24.14B |
- Stock Market
- Equities
- 1SXP Stock
